[General pharmacological studies on cis-1-acetyl-4-[4-[[2-(2, 4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl] methoxy] phenyl] piperazine].
D000818:Animals; D000935:Antifungal Agents / Q000494:pharmacology*; D001341:Autonomic Nervous System / Q000187:drug effects; D002319:Cardiovascular System / Q000187:drug effects*; D002415:Cats; D002490:Central Nervous System / Q000187:drug effects*; D004285:Dogs; D004573:Electrolytes / Q000652:urine; D005750:Gastric Juice / Q000378:metabolism; D006168:Guinea Pigs; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology*; D066298:In Vitro Techniques; D007654:Ketoconazole; D008297:Male; D051379:Mice; D009119:Muscle Contraction / Q000187:drug effects; D009130:Muscle, Smooth / Q000187:drug effects; D009132:Muscles / Q000187:drug effects; D010879:Piperazines / Q000494:pharmacology*; D011817:Rabbits; D012119:Respiration / Q000187:drug effects*
D000935:Antifungal Agents; D004573:Electrolytes; D007093:Imidazoles; D010879:Piperazines; D007654:Ketoconazole